Evaluation of Biomarkers of COPD Exacerbation
- Conditions
- SAA Level and SAA/Lipoxin A4 Ratio
- Registration Number
- NCT03609541
- Lead Sponsor
- Heidelberg University
- Brief Summary
Serum amlyoid A (SAA) was shown to act as biomarker for exacerbation of chronic obstructive pulmonary disease (AE-COPD). It seems that SAA triggers chronic inflammation by binding to ALX/PFR2 receptor. In contrast, lipoxin A4 seems to inhibit the inflammatory processes by binding to ALX/PFR2 receptor. A small trial has already demonstrated an imbalance between SAA and lipoxin A4 during AE-COPD. This study evaluates SAA level and SAA/lipoxin A4 ratio in patients with stable COPD and AE-COPD.
- Detailed Description
Patient enrolment and data aquisition is to be carried out on a prospective basis. It is planned to enrol 40 patients with stable COPD and 40 patients with AE-COPD. All patients will undergo blood sampling inlcuding SAA and Lipoxin A4.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 80
- Patients with COPD GOLD 3-4 confirmed by anamnesis and pulmonary function test
- Patient has provided written informed consent
- other reasons for worsening of symptoms (cough, dyspnea): e.g. pneumothorax, pneumonia, pulmonary embolism, myocardial infarction.
- malignant disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SAA/lipoxin A4 ratio time of exacerbation/hospitalisation, an average of 3 days SAA/lipoxin A4 ratio in stable COPD and COPD exacerbation
SAA time of exacerbation/hospitalisation, an average of 3 days SAA level in stable COPD and COPD exacerbation
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Thoraxklinik Heidelberg
🇩🇪Heidelberg, Germany